Table 1 Participant table demographics

From: Induction of lung mucosal immunity by a next-generation inhaled aerosol COVID-19 vaccine: an open-label, multi-arm phase 1 clinical trial

SARS-CoV-2 infection status

Uninfected

Previously infected

Vaccine cohort and dose (TCID50)

HuAd 1 × 105 n = 3

HuAd 1 × 106 n = 3

HuAd 1 × 107 n = 3

HuAd 3 × 107 n = 3

ChAd 1 × 105 n = 3

ChAd 1 × 106 n = 3

ChAd 1 × 107 n = 3

ChAd 3 × 107 n = 3

ChAd 1 × 108 n = 3

ChAd 3 × 107 n = 3

ChAd 6 × 107 n = 6

Sex

Male

2 (67%)

2 (67%)

2 (67%)

2 (67%)

1 (33%)

3 (100%)

2 (67%)

1 (33%)

3 (100%)

1 (33%)

4 (67%)

Female

1 (33%)

1 (33%)

1 (33%)

1 (33%)

2 (67%)

0 (0%)

1 (33%)

2 (67%)

0 (0%)

2 (67%)

2 (33%)

Age (years)*

32 (21–37)

27 (25–28)

47 (28–49)

44 (41–64)

19 (18–27)

29 (27–45)

27 (20–57)

20 (19–48)

35 (25–61)

40 (33–52)

26 (22–46)

BMI (kg/m2)

20.4 (19.9–21.1)

20.1 (16.8–23.2)

28.7 (26.0–33.7)

29.7 (24.7–32.8)

26.2 (17.6–35.2

23.4 (20.3–27.0)

25.0 (20.8–27.3)

25.1 (22.1–27.1)

26.8 (23.8–29.0)

26.1 (24.2–29.4)

28.8 (27.2–31.1)

Spirometry

Predicted FEV1 (%)

94.0 (84–106)

85.0 (78–91)

92.7 (90–97)

100 (83–114)

99.7 (92–111)

106.7 (100–114)

95.7 (86–102)

92.7 (90–97)

106.3 (98–114)

98.3 (82–112)

101.2 (87–117)

Predicted FVC (%)

97.7 (84–123)

87.7 (82–99)

92.3 (87–97)

99.0 (89–114)

103.7 (89–123)

107.7 (101–114)

104.7 (88–128)

99.3 (92–113)

109.7 (101–120)

100.0 (87–111)

103.3 (93–124)

FEV1/FVC (%)

97.7 (86–109)

97.3 (92–105)

99.7 (93–104)

104.7 (99–109)

96.0 (89–103)

98.0 (87–99)

89.0 (88–110)

93.3 (85–98)

96.7 (95–99)

97.3 (93–100)

97.7 (87–109)

mRNA vaccine history

Doses (#)*

2 (2)

2 (2)

4 (3–5)

5 (3–5)

2 (2)

3 (3)

4 (3–5)

3 (3–5)

5 (5)

5 (3–5)

3 (3–5)

Time since last dose (weeks)*

56.5 (55.25–58.25)

66 (42.75–83.5)

32.25 (24.5–80.25)

33 (25.25–79.25)

62.25 (55.25–66.25)

50.25 (39–63.75)

32.25 (32.25–80.25)

73.5 (36.75–94.5)

53.5 (40.75–56)

74.75 (73.5–153.5)

146.38 (71.25–172.5)

  1. *median
Back to article page